title: The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study.
abstract: METHODS
  This is an observational prospective noncontrolled study. We enrolled 105 patients affected by neurogenic detrusor overactivity (NDO) who underwent botulinum neurotoxin A (BONT-A) intradetrusor injection and were followed-up for 270 days.
  
  
  OBJECTIVE
  To investigate the use of oxybutynin after BONT-A administration in NDO patients.
  
  
  METHODS
  Careggi University Hospital in Florence and Tor Vergata University Hospital in Rome.
  
  
  METHODS
  Prospective data from two Italian centers were collected in 1 year. Patients showing limited efficacy but good tolerability and adherence to oxybutynin 5 mg three times a day (t.i.d.). were enrolled in the study. Patients received BONT-A intradetrusor injection (onabotulinumtoxinA, 300 U) with a trigone-sparing technique, and the use of oxybutynin was registered at every visit.
  
  
  RESULTS
  105 patients were included. At visit 1, only 30 patients (28.6%) used oxybutynin t.i.d., whereas 47 (45,2%) used a lower dosage and 28 (26.7%) stopped the therapy. At visit 2, 77.3% of patients who had reduced oxybutynin intake, maintained the dosage decided at visit 1. At visit 3, 51.9% returned to oxybutynin t.i.d.; 44.8% were on a reduced dosage and only 3 (2.9%) were not taking the drug. At visit 4, only 37.5% of patients were taking less than oxybutynin t.i.d.
  
  
  CONCLUSIONS
  This study provides some important insights on the use of oral antimuscarinics in patients treated by means of BONT-A intradetrusor administration for NDO; in particular, it suggests that, after an initial reduction in the use of oxybutynin, patients tend to increase the dosage of this drug during the follow-up after the BONT-A treatment.
authors.affiliation: Unit of Functional Urology, Policlinico Tor Vergata, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. efinazzi@tin.it
authors.forename: E
authors.initials: E
authors.lastname: Finazzi-Agrò
authors.forename: L
authors.initials: L
authors.lastname: Topazio
authors.forename: C
authors.initials: C
authors.lastname: Perugia
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
authors.forename: M
authors.initials: M
authors.lastname: Finita Celso
authors.forename: C
authors.initials: C
authors.lastname: De Nunzio
authors.forename: G
authors.initials: G
authors.lastname: Del Popolo
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000009:adverse effects*; D016009:Chi-Square Distribution; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007558:Italy; D008137:Longitudinal Studies; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000009:adverse effects*; D019370:Observation; D013119:Spinal Cord Injuries / Q000188:drug therapy; D013997:Time Factors; D053201:Urinary Bladder, Overactive / Q000139:chemically induced* / Q000188:drug therapy*; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D008333:Mandelic Acids; D009465:Neuromuscular Agents; D064804:Urological Agents; D019274:Botulinum Toxins, Type A; C005419:oxybutynin